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ABSTRACT 
Tau protein is characterized by a complex pattern of phosphorylation and is localized in 
the cytoplasm and nucleus in both neuronal and non-neuronal cells. Human AT100 nuclear 
tau, endowed by phosphorylation in Thr212/Ser214, was recently shown to decline in 
cornus ammonis 1 (CA1) and dentate gyrus (DG) in Alzheimer’s disease (AD), but a 
defined function for this nuclear tau remains unclear. Here we show that AT100 
progressively increases in the nuclei of neuronal and non-neuronal cells during aging, and 
decreases in the more severe AD stages, as recently shown, and in cancer cells (colorectal 
adenocarcinoma and breast cancer). AT100, in addition to a co-localization with the DAPI-
positive heterochromatin, was detected in the nucleolus of pyramidal cells from the CA1 
region, shown to be at its highest level in the more senescent cells and in the first stage of 
AD (ADI), and disappearing in the more severe AD cases (ADIV). Taking into account the 
nuclear distribution of AT100 during cell aging and its relation to the chromatin changes 
observed in degenerated neurons, as well as in cancerous cells, which are both cellular 
pathologies associated with age, we can consider the Thr212/Ser214 phosphorylated 
nuclear tau as a molecular marker of cell aging. 
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1. Introduction 
Cell degeneration and uncontrolled cell proliferation are two different paths of cell fate 
specifically related to diseases associated with aging, such as Alzheimer’s Disease (AD) 
and cancer, respectively (Ferrer 2012; Navarrete-Reyes et al., 2016). A number of 
studies have shown an inverse association between neurodegeneration and cancer; namely, 
patients with AD very rarely showed cancer pathologies, and conversely patients with a 
cancer history showed a very low risk for AD (Driver, 2014). Moreover, other evidence 
indicates that AD and cancer seem to be related to similar molecular mechanisms, and 
modification of the nuclear chromatin organization possibly affects both pathologies 
(Cruickshanks and Adams, 2011). 
For decades, tau has been considered a cytoplasmic tubulin binding neuro-protein, which 
plays an important role in the regulation of the microtubular network and in axonal 
formation (Povlishock et al., 1999). It has been found to be directly involved in the 
etiology of neurodegenerative disorders related to age, such as AD and other taupathies 
(Panegyres and Zafiris-Toufexis, 2002). However, more recently, the presence of tau has 
been demonstrated in non-neuronal cells, such as fibroblasts and lymphocytes, as well as in 
normal and transformed cell lines from different tissues (Cross et al., 2000; Souter and 
Lee 2009). Moreover, its expression level in several human cancers has been related to 
resistance to anti-mitotic treatments (Rouzier et al., 2005; Smoter et al., 2013). 
In vitro experiments have demonstrated tau´s interaction with DNA and a number of 
studies have shown that tau protein binds to the minor groove of dsDNA in an unspecific 
manner via the proline-rich domain (PRD) and the microtubule-binding domain (MTBD) 
(Wei et al., 2008; Qi et al., 2015) and that presents, by nuclear magnetic resonance 
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spectroscopy, multiple points of contact both in AT-rich and GC-rich 22 bp 
oligonucleotides (Qi et al., 2015). A specific binding of tau to AT-rich satellite DNA 
sequences in the nucleolus of human fibroblasts and HeLa cells was previously shown 
(Sjöberg et al., 2006), in addition to binding of α-synuclein and tau to a GC-rich DNA 
oligonucleotide in the B- and Z-forms (Vasudevaraju et al., 2012). This indicates a 
possible role for tau in nucleolar organization and gene regulation. Moreover, along this 
line of evidence, in vitro and in vivo experiments have revealed that the binding of tau to 
DNA plays a protective role in oxidative stress (Wei et al., 2008) and heat-stress 
conditions (Violet et al., 2014), and enhances chromosome stability (Rossi et al., 2008), 
with the level of protection dependent on tau concentration (Hua and He, 2003). 
The phosphoepitope AT100, which recognizes the phosphorylated Thr212/Ser214 
residues, sequentially generated by glycogen synthase kinase and protein kinase A and 
induced in vitro by polyanions such as heparin and RNA (Zheng-Fischhöfer et al., 1998), 
has been reported to be located in the nucleus of human (Hernandez-Ortega et al., 2015) 
and mouse (Gartner et al., 1998) neurons, and of cultured fibroblasts (Rossi et al., 2008). 
However, in AD neurons, AT100 progressively decreases from the nuclei disappearing in 
neurons of advanced stages of AD (Hernandez-Ortega et al., 2015), suggesting a strict 
relationship between Thr212/Ser214 phosphorylated tau with heterochromatin loss, global 
chromatin relaxation and gene expression deregulation in AD (Mansuroglu et al., 2016). 
The tau protein has not only been related to AD but also to cancer, both age-related 
diseases, and it has been suggested that aging may activate similar pathways in both 
(Souter and Lee, 2009). It is well known that nuclear aging is accompanied by chromatin 
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damage and genomic instability associated with changes in chromatin structure, such as 
heterochromatin loss (Pegoraro and Misteli, 2009). 
The aim of the present study was to gain insight into the function of nuclear tau in relation 
to the age-related chromatin modification in neurons and epithelial cells, two cell type with 
different physiological and morphological features, and to their aging related diseases, 
namely Alzheimer’s Disease (AD) and cancer respectively. We analyzed the cell 
distribution of the tau protein identified by the AT100 antibody, which recognizes 
phosphorylated Thr212/Ser214 residues. AT100 was used on human cells from healthy 
and degenerative tissues (brain, intestinal, and breast samples) at different aging stages, 
showing a progressive increase in the nucleus, during aging, especially in human senile 
hippocampal neurons. Moreover, in cancer cells AT100 signal almost disappears from the 
nucleus as well as in the AD cell nuclei, as recently shown in the case of AD neurons 
(Hernandez-Ortega et al., 2015). We also observed a nucleolar location of AT100 in the 
pyramidal cells from the CA1 region, not previously detected. The potential participation 
of the tau protein in the age-related change of chromatin organization is discussed. 
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2. Results 
The nuclear tau protein was investigated here using the antibody that recognizes the 
AT100 epitope, corresponding to tau with phosphorylation at the Thr212/Ser214 residues. 
This antibody was previously shown to detect tau protein in the nucleus from mouse and 
human brain cells (Gartner et al., 1998; Hernandez-Ortega et al., 2015). The cell 
distribution of AT100 was performed in four different human cell types at different aging 
stages: pyramidal neurons from the CA1 region, granular neurons from the dentate gyrus 
(GD), epithelial cells from colorectal mucosa and from acinar cells. We also analyzed the 
distribution of AT100 in pyramidal neurons from CA1 region of subjects with AD, and in 
tissue sections of colorectal adenocarcinoma, or breast cancer (see suppl. Tab. 1 for 
description of the cases used). 
2.1. AT100 in the human neurons from the CA1 region 
We analyzed, by classical immunohistochemistry and by immunofluorescence 
analysis with confocal laser scanning microscopy (CLSM) of brain sections, the 
distribution of AT100 tau epitope in the CA1 region of the hippocampus. We observed 
AT100 in the nucleus of the pyramidal neurons with a progressively, statistically 
significant, increasing amount from healthy young to senile (Fig. 1). More precisely, 
AT100 is very low and in few cells in younger samples and progressively increases in the 
adult ages, reaching the highest levels at the senile stage (Fig. 1H and Fig. 1I). In this 
latter stage, AT100 is very evident in relation to the more compact chromatin, especially 
around the nucleolar region of the pyramidal cells (Fig. 1F and Fig. 1G). In the adult and 
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senile stages, a weak AT100 signal was seen in the cytoplasmic compartment in the initial 
part of the axonal dendrites (Fig. 1). 
Immunofluorescence and CLSM analyses refined the nuclear distribution indicated 
above. AT100 co-localized with the more compact chromatin (DAPI-positive) and 
presented a detectable amount in the nucleolus of pyramidal cells from the CA1 region, as 
demonstrated by the co-localization with the nucleolar marker upstream binding factor 
(UBF) (Fig. 2). AT100 progressively increases in the nucleus, and more specifically in the 
nucleolus of the neurons from young to senile subjects and in the first stages of AD (ADI, 
classification according to Braak and Braak, 1991), disappearing from the nucleus of 
degenerated pyramidal cells at the AD-IV stage, corresponding to those cells with a high 
amount of neurofibrillar tangles (NFT) (Fig. 2). The difference of AT100 presence in the 
nuclei of ADI neurons respect to senile is not statistically significant (Fig. 2H). 
In summary, the presence of AT100 in the nucleus increases through aging reaching 
the highest levels in senile neurons. The increase of AT100 is statistically significant 
considering the amount of protein in the nucleus (Fig. 1I) as well as considering the 
number of cells containing AT100 (Fig. 1H and Fig. 3). However, as has been previously 
described (Hernandez-Ortega et al., 2015), in AD neurons dramatic changes occur at 
nuclear AT100 that progressively disappears from the early stage. In more advanced 
stages, such as in ADIV, the AT100 signal disappears from the nuclear and nucleolar 
chromatin, concomitantly with its appearance in the cytoplasm forming the pathologic 
NFTs, even if other neurons lack AT100 in the nucleus and cytoplasm (Fig. 2E). 
2.2. AT100 in the human neurons from the DG region 
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The presence of AT100 in the DG region in healthy young and senile samples was 
clearly visible, with a larger amount in the senile granular neurons compared to the 
younger ones (Fig. 4). However, AT100 did not reach the same level observed in the 
nuclei of the senile pyramidal neurons (see Fig. 1I and Fig. 4H). In senile granular 
neurons, AT100 forms large accumulation blocks, which are very evident at the periphery 
of the nucleus, a nuclear compartment largely corresponding to the GC-poor chromatin. 
No evident signals were detected in the cytoplasm of these cells. AT100 signals were not 
detectable, or detectable at very low amount, in fetal neurons (Fig. 4). 
These results show a similar pattern of nuclear AT100 distribution in DG and CA1 
neuronal cells, with an evident colocalization of AT100 with nuclear heterochromatin and 
its progressive increase in the nucleus related to age. However, the very high amounts 
observed in the senile pyramidal neurons are not seen in the granular neurons. 
2.3. AT100 in the replicative human neoplastic and non-neoplastic cells 
The AT100 epitope was detected in the nucleus of healthy young and senile replicative 
epithelial cells from intestinal mucosa (Fig. 5) and breast acinar cells (Fig. 6). In both 
types of cells, AT100 presents a distribution of scattered spots throughout the nuclear 
chromatin, prevalently at the nuclear periphery. This is more evident in the senile epithelial 
cells of colorectal mucosa where AT100 increases about four times respect to the normal 
young epithelial cells (Fig. 4G), forming larger blocks of signal. In the nucleus of the 
colorectal neoplastic cells, the signal amount of AT100 generally decreases at the level of 
the young epithelial cells but remains in some large, more compact spots that occupy 
nearly the entire periphery of the nucleus (Fig. 4G). However, in the neoplastic cells of 
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breast carcinoma the AT100 staining significantly increases in the degree I of the 
carcinoma (about five times respect to the healthy breast) and decreases in malignant cells 
of degree III (Fig. 5J). In cytoplasm from young and senile non-neoplastic epithelial cells 
of colorectal mucosa the presence of AT100 protein is low, and in the neoplastic cells it is 
always absent. A very similar situation in the cytoplasm was observed in breast cells, both 
neoplastic and non-neoplastic. 
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3. Discussion 
During cellular aging, alterations in the organelle function are progressively shown to 
be associated with biological wearing away and environmental stress. These alterations are 
related to changes in chromatin organization, which directly affects proper gene 
expression, suggesting that nuclear alteration could contribute to aging (Feser and Tyler, 
2011; Cruickshanks and Adams, 2011). Tau is a relevant protein involved in the axonal 
formation and cytoplasmic aggregates NFT specifically observed in the age-related 
Alzheimer’s disease (Ayyadevara et al., 2016), but has also been biochemically 
demonstrated in the cell nuclei and by immunofluorescence in the nucleolus (Sjöberg et 
al., 2006; Bukar Maina et al., 2016). Here, we studied by immunohistochemistry and 
immunofluorescence the AT100 epitope of nuclear tau and its relation to cell aging and to 
aging pathologies. 
3.1. Nuclear tau during cell aging 
We detected AT100, the nuclear tau endowed by phosphorylation in Thr212/Ser214, 
in the nucleus of neuronal and epithelial cells, in agreement with some previous results 
showing AT100 in the nucleus of mouse and human neurons (Gartner et al, 1998; 
Hernandez-Ortega et al., 2015), and of cultured fibroblasts (Rossi et al., 2008). In 
addition, our results showed that the amount of AT100 increases with age, reaching its 
maximum level at the senile stage. Moreover, it co-localizes with the most intense DAPI 
staining that corresponds to the most compact chromatin prevalently present at the 
periphery of the nucleus, adjacent to the nuclear membrane, and containing DNA largely 
composed of the very GC-poor, and very gene-poor, L1 isochores (Bernardi 2015). The 
distribution of the chromatin in the nucleus according to the GC-level is evolutionarily 
conserved and related to the nuclear chromosomal organization (Federico et al., 2017), 
determining an ordered gene positioning relevant for a number of cell activities, both 
normal (e.g., cell differentiation) and abnormal (e.g., the onset of genetic diseases) 
(Ballabio et al., 2009; Leotta et al., 2014). We also detected a nucleolar location of 
AT100 in the pyramidal cells of the CA1 region, according to previous demonstration that 
tau interacts with the nucleolar repetitive alpha satellite DNA, in the AT rich sequences 
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(Sjöberg et al., 2006), further indicating a correlation between tau and heterochromatin. 
Statistical evaluation of results indicated that tau increases during aging not only in the 
amount of protein present in the nuclei, but also in the number of cells with detectable 
amount of AT100, reaching its maximum levels at the senile stage. 
Our data indicate a possibly different type of interaction between AT100 and nuclear 
DNA depending on whether the cell is young or senile. Moreover, the increase in the 
AT100 interaction with heterochromatin seems to be strikingly different in aging epithelial 
cells and granular neurons compared to pyramidal neurons of the CA1 region, possibly 
related to the differences in the proliferative vs post-mitotic status of the cells 
characterizing the epithelial and the DG tissues respect to CA1 (von Bohlen und Halbach, 
2011). In the former case, AT100 forms large blocks of protein accumulation whereas in 
the latter it is more diffuse in the nuclei with few large blocks of accumulation, particularly 
in relation to the nucleolus. Thus, the reprogramming of chromatin organization during 
aging seems to be different in proliferative versus post-mitotic or differentiated cells. 
Considering the above observations, we can speculate on a possible involvement of 
tau, and specifically of the AT100 epitope, in the heterochromatin organization and or 
protection during cell life. We propose that the AT100 phosphoepitope could interact with 
repetitive DNA from interphasic chromatin to maintain the more compacted status, thus 
increasing in amount with the increasing level of mutation/alteration affecting the more 
compact chromatin positioned at the nuclear periphery during aging (Feser and Tyler, 
2011), interacting and protecting heterochromatin in the case of aged cells. Moreover, a 
high degree of heterochromatic pattern in rDNA is a normal condition in differentiated 
cells (Sanij and Hannan, 2009; Takada and Kurisaki, 2015), and the presence of tau in 
this context could enhance and protect this condition. 
3.2. Nuclear tau and aging pathologies 
AT100, further to the increase in the nucleus during cell aging, drastically decreases in 
derived pathological conditions such as AD and cancer. Recently, the work of 
Mansuroglu et al. (2016) and Hernandez-Ortega et al. (2015) have revealed a 
relationship between nuclear tau and conformational changes in global chromatin in 
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pyramidal neurons of early AD, which is maintained throughout the development of the 
disease. It is also known the dramatic nuclear change takes place between aging neurons 
and AD neurons, possibly related to an aberrant attempt to re-enter into the cell cycle 
associated with aging stress (Zhu et al., 1999) and these events may begin the 
neurodegenerative process associated with age (McShea et al., 2007). In this sense, the 
changes observed in the nuclear tau distribution in aging cells with respect to younger 
cells, and even more so with AD neurons, could be associated to modifications of the 
chromatin organization determining alterations in gene expression (Tan et al., 2010; 
Arhondakis and Kossida, 2011). 
A number of studies have demonstrated the presence of non-phosphorylated tau (Tau-
1) in the nucleolus (Loomis et al., 1990; Thurston et al., 1996, 1997; Sjoberg et al., 
2006; Rossi et al., 2008), and now we observed for the first time a nucleolar location of 
AT100 in the pyramidal cells of the CA1 region, that could indicate a further involvement 
in chromatin organization, in this case related to the rDNA sequences, as the loss of 
nucleolar heterochromatin has been shown to trigger accelerated aging and that 
heterochromatin prevents recombination between rDNA repeats, thereby preserving the 
nucleolar structure (Sinclair and Guarente, 1997; Peng and Karpen, 2007). Besides, 
during the development of AD we observed that, at the start of disease (stage I), the 
nucleolar AT100 increases in consonance with the nucleolar hypertrophy described in 
hippocampal neurons, while the evident reduction in nucleolar volume observed in stages 
IV-V matches the absence of AT100 in the nucleolus (Iacono et al., 2008). Globally, the 
data presented may suggest that the absence of AT100 at the more severe AD stage could 
be related to the loss of cell control on the genomic DNA and more specifically, in the 
maintenance of the correct heterochromatic patterns in the cell nuclei, including the 
nucleolus (Falk et al, 2014).  
In epithelial cells the chromatin dynamics during aging are manifested differently, but 
it is widely accepted that aging stress can lead to tumoral development (Serrano and 
Blasco, 2007). Our results show for the first time a regression of the amount of nuclear tau 
in cancer cells, especially in the more severe stages, compared to senile cells or to the less 
severe stage of the disease. Until now, research performed on tau and cancer have focused 
on the expression levels in relation to the cytoplasmic microtubular function in cell 
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division and to the anti-mitotic activity of taxol (Rouzier et al., 2005; Smoter et al., 
2013). Nevertheless, it has been shown that a large proportion of tau does not bind MTs in 
prostate cancer cells, suggesting a different role for tau in cancer cells (Souter and Lee, 
2009). The presence of AT100 in the nucleus of the colorectal and breast carcinoma 
neoplastic cells should encourage new investigations to understand the function of nuclear 
tau and whether this is related in the change of chromatin organization in tumoral cells 
(Carone and Lawrence, 2013). 
3.3 Conclusions 
In this work we showed for the first time a gradual accumulation of nuclear tau in 
human cells during aging and its general co-localization with the DAPI-positive 
heterochromatin. This could indicate a possible role of nuclear tau in the organization 
and/or protection of chromatin in the cells during aging (Pegoraro and Misteli, 2009). 
Moreover, this seems to be related to aging pathologies (neurodegenerative or cancerous 
diseases), where nuclear AT100 decreases drastically, a condition very evident in the more 
severe stages of the diseases. Anyway, further investigation is needed to better understand 
the role of phosphorylated AT100 nuclear tau in chromatin aging. 
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4. Experimental procedures 
4.1. Tissue samples 
Brain samples were obtained from the Institute of Neuropathology HUB-ICO-
IDIBELL Biobank. Colon mucosa, appendiceal, breast cancer and colorectal 
adenocarcinoma samples were obtained from Department of Pathology of Hospital 
Universitario Fundación Alcorcón (HUFA) (see suppl. Tab. 1). These patients had not 
received previous radiation or chemotherapy. All procedures performed in the present 
study, involving human participants, were in accordance with the ethical standards of the 
institutional and/or national research committees and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards. 
Tissues and sections were prepared as previously described (Hernandez-Ortega et 
al, 2015). The brain regions examined in the present study were the CA1 region of the 
hippocampus and the Dentate Gyrus. Non-neoplastic colon mucosa and adenocarcinoma 
tissues from the appendix and colon were selected to compare. Age groups were: young 
(between 20 to 40 years), adult (between 40 to 60 years) and senile (more than 60 years). 
4.2. Immunohistochemistry 
Immunohistochemical localization of the phosphorylated tau at Thr212/Ser214 
residues was carried out with the AT100 antibody (Thermo Fisher Scientific, Rockford, 
USA) on 4 µm paraffinated sections. Tissue sections were dewaxed using standard 
protocols. Antigen retrieval was performed using a low pH 6.0 citrate buffer 
(Dakocytomation, Glostrup, Denmark) at 96 °C for 20 minutes in a Dako PTLink 
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(Dakocytomation, Glostrup, Denmark) automated retrieval unit. The procedure was carried 
out with a Dako Autostainer Link48 (Dakocytomation, Glostrup, Denmark). 
Briefly, after blocking of endogenous peroxidases with Dako Peroxidase Blocking 
Reagent (DakoCytomation, Glostrup, Denmark), and a pre-incubation step of 1 hour at 
37°C with a blocking solution containing bovine serum albumin, specimens were 
incubated with primary antibody AT100 diluted 1:100 in Dako Antibody Diluent 
(Dakocytomation Glostrup, Denmark) for 30 minutes at room temperature. The staining 
was visualized using EnVision FLEX+mouse (linker) (DakoCytomation Glostrup, 
Denmark), and with 3’3-diaminobenzidine tetrahydrochloride (DAB) chromogenic reagent 
and hematoxylin counterstain. All incubation steps were performed at room temperature 
and between incubations sections were washed with Dako wash buffer. The IHC staining 
includes a positive control for the AT100 antibody. 
4.3. Immunofluorescence and CLSM analyses 
Paraffin-embedded sections for immunofluorescence experiments were treated as 
previously described (Oliveira et al., 2010; Scuderi et al., 2014). Briefly, they were 
placed at 55° C for 20 minutes, dewaxed in xylene and rehydrated in graded alcohols. To 
reduce auto-fluorescence, sections were then boiled in citrate buffer (10 mM sodium 
citrate, pH 6) and treated with Sudan Black B for 30 min at room temperature. Before the 
incubation with primary antibody, a pre-incubation step of 1 hour at 37°C with blocking 
solution (non-fat dry milk or bovine serum albumin) was carried out. Double 
immunodetections were obtained by incubation with specific primary mouse AT100 
(Thermo Fisher Scientific, Rockford, USA, 1:100 dilution) and goat UBF-1 (Thermo 
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Fisher Scientific, Rockford, USA 1:100 dilution) antibodies. After PBS rinses, specimens 
were incubated with FITC-conjugated anti-mouse and TRITC-conjugated anti-goat 
secondary antibodies (Sigma-Aldrich, 1:700 dilution). Experiments were repeated at least 
three times to confirm results. Images were obtained with a confocal laser scanning 
microscope (CLSM) Zeiss LSM700 equipped with 40x and 63x objectives. ZEN2010 
software was used for image acquisition and 3D reconstructions. 
4.4. Cell counting and statistical analysis 
Cell counting and statistical analyses were performed as previously described 
(Hernandez-Hortega et al., 2015). In details, cells were counted on 4-µm-thick sections 
for the immunohistochemistry, and on 0.5-µm scanned images for the immunofluorescence 
data obtained with CLSM. Three to six cases per group were analyzed. The number of 
AT100 positive cells was obtained in three optical fields at 400X magnification; the total 
number and the percentage of AT100 positive cells per each section were taken in 
consideration. Intensity level of AT100 signal was evaluated using the ImageJ software 
(NIH, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html). Mean data were 
analyzed with one-way ANOVA followed by Tukey’s test post hoc analysis or by two tails 
T-test. Differences between groups were considered significant at *P<0.05, **P<0.01 and 
***P<0.001. 
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Figure legends 
Figure 1. AT100 epitope in pyramidal neurons from the CA1 region at different ages. 
Representative pyramidal neurons from the CA1 region of young (20-40 years) (A, D), 
adult (40-60 years) (B, E), and senile (more than 60 years) (C, F, G) brains, respectively. 
Nu: nucleolus. Scale bar in A, B, C: 100 µm: in D, E, F, G: 10 µm. (H) Total and relative 
number of the positive AT100 cells. (I) Relative quantification of the AT100 stain 
normalized respect to the young group. Data are expressed as the mean ± standard error of 
the mean (SEM) of three (young and adult) or six (senile) cases per group. Young and 
adult groups are always statistically different respect to senile (*** P<0.001). 
Figure 2. Co-localization of AT100 epitope with the nucleolar marker UBF in 
pyramidal neurons from the CA1 region at different ages and in AD. Representative 
pyramidal neurons from the CA1 region of young (20-40 years) (A), adult (40-60 years) 
(B), senile (more than 60 years) (C), ADI (D) and ADIV (E) brains, respectively. Images 
show dual-color immunofluorescences to detect tau epitope AT100 (green signals) and 
nucleolar marker Upstream Binding transcription Factor RNA polymerase I (UBF) (red 
signals). White arrows indicate the co-localization of AT100 and UBF in the nucleolus. 
Yellow arrows indicate two affected cells from ADIV with neurofibrillary tangles (NFT) 
and a degraded nucleus. In the ADIV panel, the disappearance of UBF from the nuclei and 
its localization in the cytoplasm, decorating NFTs, is evident, as previously shown 
(Hernandez-Ortega et al., 2015). Quantitative data were in Fig. 3. Images were obtained 
with 630x magnification. A-E: merged signals (AT100+UBF) and DAPI staining (blue). F-
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J: AT100 signals (green signals). K-O: UBF signals (red signals). P-T: DAPI staining 
(blue). Scale bar, shown in panel T: 20 µm. 
Figure 3. Quantification of the positive AT100 pyramidal neurons from the CA1 
region. The total and relative number of AT100 positive cells were shown. Data are 
expressed as the mean ± standard error of the mean (SEM) of three (young, adult, ADI and 
ADIV) or six (senile) cases per group. Young, adult and ADIV groups are statistically 
different respect to senile (*** P<0.001). ADI respect to senile is not statistically 
significant (NS: not significant). 
Figure 4. Immunohistochemistry analysis of AT100 epitope of tau protein in granular 
neurons from the dentate gyrus (DG) at different ages. Granular neurons from the DG 
of fetus (8-12 weeks) (A, D), young (20-40 years) (B, E), and senile (more than 60 years) 
(C, F) brains. There is no cytoplasmic AT100 signal in the analyzed cells. DG: dentate 
gyrus; inm: inner nuclear membrane. Scale bar in A, B, C: 100 µm; in D, E, F: 10 µm. (G) 
Total and relative number of the positive AT100 cells. (H) Relative quantification of the 
AT100 stain normalized respect to the young group. Data are expressed as the mean ± 
standard error of the mean (SEM) of three (fetus and young) or six (senile) cases per 
group. Fetus and young groups are always statistically different respect to senile (*** 
P<0.001). 
Figure 5. AT100 epitope in non-neoplastic colorectal mucosa, and neoplastic cells 
from adenocarcinoma. Epithelial cells from intestinal mucosa of young (20-40 years) (A, 
D), senile (more than 60 years) (D, E) and neoplastic tissue (C, F), respectively. The 
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AT100 isoform of the tau protein was localized in low and high amounts in the cytoplasm 
(Cy) and in the nuclei (n), in young and senile cells, respectively. In neoplastic cells, 
AT100 largely decreases in both the cytoplasm and nuclei. The immunosignal is more 
evident in the internal side of the nuclear membrane (inm) in the young, senile and 
neoplastic cells. Scale bar in A, B, C: 10 µm; in D, E, F: 5 µm. (G) Quantification analysis 
of the AT100 stain in the cell nuclei normalized to the young group. Data are represented 
as mean ± standard error (SEM). Young and neoplastic groups are statistically different 
respect to senile (*** P<0.001). 
 
Figure 6. AT100 epitope in non-neoplastic and neoplastic breast cells. AT100 was 
localized in the nuclei of non-neoplastic cells and two types of breast carcinoma (grades I 
and III). In neoplastic cells, AT100 largely decreases in the nuclei of the more severe grade 
of carcinoma with respect to the less severe. Scale bar in A, D, G: 100 µm; in B, C, E, F, 
H, I: 10 µm. (J) Quantification analysis of the AT100 stain in the cell nuclei normalized to 
the healthy breast group. Data are represented as mean ± standard error (SEM). Healthy 
breast and BC-III groups are statistically different respect to BC-I (*** P<0.001). 
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Supplementary Table 1: Summary of the cases used. 
Case n. Tissue type Diagnosis Age (years) Cause of death 
1 Brain ND 21 Non natural 
2 Brain ND 27 Non natural 
3 Brain ND 32 Non natural 
4 Brain ND 45 Non natural 
5 2 Brain ND 58 Non natural 
6 2 Brain ND 63 Non natural 
7 Brain ND 65 Non natural 
8 3 Brain ND 68 Non natural 
9 3 Brain ADI > 70 AD 
10 3 Brain ADIV > 70 AD 
11 3 Brain ND 8-12 weeks Miscarriage 
12 3 Breast BC grade I 50 - 65 Alive 
13 4 Breast BC grade III 50 - 65 Alive 
14 Colon Acute appendicitis 23 Alive 
15 Colon Follicular hyperplasia lymphoid 31 Alive 
16 Colon Adenoma 40 Alive 
17 Colon Adenocarcinoma 54 Alive 
18 2 Colon Adenocarcinoma 68 Alive 
19 3 Colon Follicular hyperplasia lymphoid 68 Alive 
20 Colon Diverticulitis 79 Alive 
ND: not determined. AD, ADI, ADIV: Alzheimer’s diseases stages of Braak and Braak; BC: breast 
cancer 
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Abbreviations: 
 
AD:  Alzheimer’s disease 
ADI-ADIV Stages of AD following Braak and Braak (1991) classification 
AT100: Tau epitope with phosphorylated Thr212/Ser214 residues 
CA1:  Cornus ammonis 1 
CLSM:  Confocal laser scanning microscopy 
DAPI: 4′,6-diamidino-2-phenylindole 
DG:  Dentate gyrus 
FITC: Fluorescein isothiocyanate 
MAPT : Microtubule-associated protein tau gene 
MTBD:  Microtubule-binding domain in tau protein 
PRD:  Proline-rich domain in tau protein 
TRITC: Tetramethylrhodamine isothiocyanate 
UBF:  Upstream binding factor 
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Highlights 
 
 
AT100 nuclear tau progressively increases in the cell nuclei during aging 
 
Phosphorylated AT100 nuclear tau is a putative molecular marker of cell aging 
 
AT100 nuclear tau was detected in the nucleolus of pyramidal cells from CA1 region 
 
AT100 nuclear tau disappears from pyramidal cells of CA1 region during AD progression 
 
 
